NVP-2, a novel small molecule inhibitor, can effectively and selectively inhibit the activity of CDK9 by blocking the binding site of ATP.20 It has shown effectiveness in treating T-ALL cell lines and melanoma cell lines.20,21 This study illustrates how NVP-2 reduced AML cell proliferation and provides a theoretical basis for our future research. Here, CDK9 is linked to melanoma.